argued that chemotherapy-resistant HCC cell-released IL-6 boosts the silencing and activity of MDSCs and, when anti-IL6 neutralizing antibody is combined with 5-FU chemotherapy, tumor growth is significantly decreased (80). This evidence concerns the gene IL6 and hepatocellular carcinoma.